Abstract
Alpha-Klotho (α-Klotho) was serendipitously discovered as a suppressor of premature organ failure, which resembles premature aging. Animal experiments and human observational studies indicate that α-Klotho deficiency is associated with a wide spectrum of diseases, and α-Klotho is a promising biomarker for both early detection and prediction of outcome in human kidney disease. Moreover, preclinical data support that α-Klotho deficiency is not only a biomarker but also a pathogenic factor for kidney and nonkidney diseases. Therefore, strategies to increase circulating α-Klotho could prevent or treat certain diseases. In this chapter, we discuss different α-Klotho measurements in humans and rodents and summarize evolving preclinical data supporting the potential therapeutic application of α-Klotho although no human clinical trials have been yet conducted. Finally, we briefly discuss the potential challenges and opportunities to target α-Klotho for the diagnosis and treatment of human diseases, with emphasis in kidney disease.
Original language | English (US) |
---|---|
Title of host publication | Fibroblast Growth Factor 23 |
Publisher | Elsevier |
Pages | 265-298 |
Number of pages | 34 |
ISBN (Electronic) | 9780128180365 |
DOIs | |
State | Published - Jan 1 2021 |
Keywords
- Acute kidney injury
- Aging
- Biomarker
- Cardiovascular disease
- Chronic kidney disease
- Dementia
- Kidney fibrosis
- Prognosis
- Therapy
- Tumor
- α-Klotho
ASJC Scopus subject areas
- General Medicine